

Amendments to the Specification:

Please delete the present Abstract and replace with the following paragraph (marked with deletions indicated by strikethrough and insertions by underlining.)

Polynucleotides encoding chimeric or humanized LL2 monoclonal antibodies (mAbs) or fragments thereof are described in which the CDRs of the light and heavy chains of the murine LL2 anti-B-lymphoma, anti-leukemia cell monoclonal antibody have been recombinantly joined to the human kappa and IgG1 constant region domains, respectively, which has reduced tendency of eliciting human anti-mouse (HAMA) response in humans compared to the murine LL2 mAb. The humanized LL2 monoclonal antibody further comprises CDRs of the light and heavy chains that have been recombinantly joined to a framework sequence of human light and heavy chains variable regions. Vectors for producing recombinant chimeric and humanized chimeric monoclonal antibodies are provided.